ESPE Abstracts

This review summarizes the prevalence and degree of functional brain changes detected by fMRI in Growth Hormone Deficiency (GHD) patients and their clinical associations in studies from 2019 to 2024Results: Author Year Prevalence of F...

This comprehensive literature review identified studies reporting MRI findings related to pituitary volume in children with GHD. Studies were selected for their relevance to clinical correlations involving short stature, GH peak levels, IGF-1 levels, and therapy response.Results: The 30 studies reviewed highlight significant structural abnormalities in the pituitary gland of children GHD. Key findings include anterior pituitary hypoplasi...

Introduction: This study presents a comparative analysis of the efficacy of sex steroid priming in enhancing growth hormone (GH) responses in short stature children undergoing GH stimulation tests.Methods: A randomized study encompassed a cohort of 40 children, divided into two groups: "With Priming" and "Without Priming". The primed group exhibited a higher peak GH response (6.53) compared to the non...

Introduction: Growth hormone (GH) therapy in Turner Syndrome (TS) affects growth and glucose metabolism.Methods: Reviewed studies focused on GH therapy's impact on glucose metabolism in TS, selecting those with clear outcomes and sufficient sample sizes.Results: The effects of GH therapy on glucose metabolism in TS vary, with studies indicating both potential risks and benefit...

Objective: Allostatic load (AL) refers to the physiological response that occurs in chronic stress burden, Excessive weight gain is an important source of physiological stress promoting chronic low-inflammation state detrimental for health. We estimated AL score among a pediatric population, in order to define a correlation between cumulative biological dysregulation and excess weight.Methods: We enrolled 164 children an...

Introduction: Managing pediatric hypothyroidism with thyroxine therapy is crucial for children's growth and development. This presents a synthesized overview of the relationship between thyroxine therapy and growth outcomes in children with congenital and acquired hypothyroidism.Methods: A literature review from 1987 to 2013 was conducted, selecting studies on thyroxine therapy's effects on linear growth, cogni...

Introduction: Subclinical hypothyroidism (SCH) in children, characterized by elevated thyroid-stimulating hormone (TSH) levels with normal free thyroxine (T4) levels, presents a clinical dilemma. The decision to treat SCH with L-thyroxine versus adopting a watchful waiting approach hinges on the potential benefits and drawbacks.Aim: This review synthesizes evidence from 20 studies to assess the impact of treatment versus...

Introduction: This review aims to chronologically summarize MRI findings in children with GHD, correlating these changes with clinical characteristics and GH testing results, and IGF-1 levels.Methods: We reviewed MRI studies conducted from 1991 to 2024, focusing on structural and functional brain changes in children with GHD. Data were extracted from various studies and arranged chronologically.<st...

Introduction: Growth hormone therapy is a cornerstone treatment for children with GHD and ISS. Its impact on the hypothalamic-pituitary-thyroid axis, however, has been a subject of ongoing research.Review of Literature:Early Observations (1992-2005): Pirazzoli et al. (1992) and Tang et al. (1997) were among the first to document changes in thyroid function due to ...

Encouraged by unimolecular dual incretin co-agonists (GLP1/GIP) to enhance glycemic efficacy (Finan et al. 2013, Sci Transl Med) and GLP1/glucagon co-agonists to enhance weight loss efficacy (Day et al. 2009, Nat Chem Biol) and to restore diet-induced leptin sensitivity (Clemmensen et al. 2014, Diabetes), we recently developed the first tri-agonist (GLP1/GIP/glucagon) for the treatment of metabolic disorders (Finan et al. 2014, Nat Med). Importantly, this concerted triple agon...